Expanding Access to Care in Multiple Myeloma
- Ira Zackon discussed data on the use of bispecific antibodies for multiple myeloma, presented at ASH 2025.
- In essence, the article highlights the growing use of bispecific antibodies in multiple myeloma treatment and the need to ensure equitable access to these therapies, particularly within community...
Hear’s a summary of the provided text:
Key Points:
* Bispecific Antibodies in Multiple Myeloma: Dr. Ira Zackon discussed data on the use of bispecific antibodies for multiple myeloma, presented at ASH 2025.
* Real-World Representation: The study included diverse populations (Black Americans and rural residents) often excluded from clinical trials, but more research is needed.
* Community Oncology Access: Dr. Zackon emphasized the importance of delivering these treatments in community oncology settings too improve patient access and convenience.
* Source: The information comes from Healio interviews.
* Disclosure: Dr. Zackon is currently employed by McKesson.
* Healio AI: The article promotes Healio AI as a resource for clinical questions, offering access to a broad knowledge base.
In essence, the article highlights the growing use of bispecific antibodies in multiple myeloma treatment and the need to ensure equitable access to these therapies, particularly within community oncology practices.